Pharmaceutical Labeling Requirements: FDA, EU Rules & GMP Packaging Controls

A carton may say 10 mg while the blister inside contains 20 mg tablets, or a bottle may carry the previous batch's expiry date. Pharmaceutical labeling requirements address both the information patients need and the controls that connect it to the correct medicine.

US and EU labeling rules differ, but packaging teams face the same challenge: matching approved artwork, components, and variable data. The following explains the FDA and EU rules and how GMP controls and machines apply them.

What Information Must Appear on Pharmaceutical Labels?

Start with the finished pack in your hand. It may include an immediate container—the bottle or blister touching the medicine—an outer carton, and a leaflet. Their required information depends on the approved product and market; there is no global template.

Most pharmaceutical labels help a user answer three questions: What medicine is this? How should it be used safely? Can this pack be traced? The table explains common fields, not a universal list of legal requirements.

A batch number and a serial number are not the same. All cartons from one production batch can share its lot number, while each carton may receive a different serial number under an applicable serialization system. A readable barcode can still be printed on the wrong product.

For code definitions, see our medicine label codes guide. Here we focus on regulatory requirements and packaging control.

What Are the FDA Pharmaceutical Labeling Requirements?

For medicines sold in the United States, the first distinction is prescription versus over-the-counter (OTC). They use different labeling formats. 21 CFR Part 201 governs drug labeling; Part 211 addresses controls against packaging mix-ups. Always start with the product's approved or otherwise applicable labeling.

Prescription drugs: the carton is not the full prescribing information

Prescription medicines need information on uses, dosing, contraindications, warnings, and adverse reactions. For products within their scope, 21 CFR 201.56 and 201.57 set out the content and format of this prescribing information, including the Highlights and Full Prescribing Information sections.

The entire prescribing document does not belong on a bottle label. The physical package has its own requirements; teams control container labels, cartons, and prescribing-information materials separately.

Imagine a manufacturer supplying the same tablet in 10 mg and 20 mg strengths. Cartons can look similar, and both blister sizes may fit one cartoner. Before running the 10 mg order, the team must confirm that the printed blister foil, carton, and insert all belong to the 10 mg presentation. A perfectly printed 10 mg carton containing a 20 mg blister is still the wrong package. Printer checks alone will not catch this.

OTC medicines: what the Drug Facts panel contains

Most US OTC medicines use a standardized Drug Facts panel. 21 CFR 201.66 establishes its standardized sections, including Active ingredient, Purpose, Uses, Warnings, Directions, Other information, and Inactive ingredients, subject to the applicable rules and exceptions.

Consider two cold-medicine cartons with nearly identical branding but different active ingredients or directions. Old artwork might carry the right batch code but the wrong warning. The packaging check must therefore identify the approved Drug Facts version, not simply confirm that some label was applied. Do not apply the OTC template to prescription drugs.

Drug barcodes and DSCSA product identifiers are different

Barcode rules are separate. 21 CFR 201.25 covers specified prescription drugs, biological products, and certain hospital-use OTC medicines, with exclusions and exemptions. For covered products, the rule generally calls for a linear barcode containing the appropriate National Drug Code (NDC).

The Drug Supply Chain Security Act (DSCSA) deals with serialized product identification and tracing for covered prescription-drug packages and homogeneous cases. It differs from Part 201 barcoding. Specify each coder's required data, format, and verification point; a scanner can otherwise pass the wrong code.

What Are the EU Pharmaceutical Labeling Requirements?

EU rules distinguish outer packaging, immediate packaging, and the leaflet. Directive 2001/83/EC, particularly Articles 54–63, describes the key particulars, presentation, and language rules. EMA QRD templates help lay out approved text but do not replace legislation.

Outer cartons and immediate containers carry different information

Under Article 54, the outer package—or immediate packaging where no outer package exists—must display specified particulars. These include product identity, relevant composition and administration information, contents, applicable warnings, expiry, batch number, and authorization details. Artwork must match the authorized product and market.

Article 55 then deals with immediate packaging. Cartons offer more print space than blister foil, which also carries sealing and cutting features. For qualifying blisters enclosed in an outer carton, Article 55(2) permits a shorter set of particulars, including the medicine name, marketing authorization holder, expiry date, and batch number. Do not assume the same reduced set is sufficient for a blister sold without the outer carton.

Maintain distinct, linked carton and foil artworks. For a new market, check whether the foil, leaflet, and language must change too.

Leaflets, language, and Braille are part of the packaging job

The leaflet is a regulated component. Articles 58–59 address whether a package leaflet is needed and what it must contain, subject to applicable conditions; Articles 56 and 56a address presentation and Braille, and Article 63 addresses market language requirements and exceptions.

On a cartoning line serving several EU markets, two leaflets may be folded to exactly the same size. A presence sensor confirms insertion, not necessarily whether it is German or French. Identity checks and controlled material issuance address this risk. EMA's current human QRD annotated template, version 10.4, is a useful reference when preparing this artwork.

Which packs need an EU Data Matrix and anti-tampering device?

Not every medicine sold in the EU needs serialization. Article 54a and Commission Delegated Regulation (EU) 2016/161 establish safety-feature requirements for medicines within their scope, with defined inclusions, exclusions, and exceptions. Covered packs generally require a unique identifier and an anti-tampering device.

The unique identifier includes a product code, serial number, batch number, expiry date, and an additional national number where applicable. It uses a 2D Data Matrix, generally on the outer carton when present.

The line must receive serial data, print it on the correct carton, verify content and quality, and manage rejected identifiers. Article 6 of Regulation 2016/161 addresses print quality; it should not be treated as a blanket specification for every scanner or medicine.

How Do These Requirements Change for Blisters, Bottles, and Cartons?

The same information creates different risks on blister foil, bottle labels, and cartons. The line must control the components that identify each pack.

Blister foil: the risk often starts before coding

A blister packaging machine forms or supplies cavities, fills them with tablets or capsules, and seals them with lidding material. If the wrong preprinted foil roll is loaded, every sealed blister can display the wrong product name or strength even when the sealing process is technically sound.

Before startup, verify foil identity; then check registration and lot/expiry data on the first accepted blisters and at defined intervals. Product-presence inspection detects empty cavities; it does not by itself verify that the correct foil artwork was used. A downstream cartoner must still match product to carton.

Bottles: matching the label to what was filled

On a tablet or capsule counting and bottling line, the sequence might be counting, filling, capping, induction sealing, label application, and coding. Match bottle size, label roll, and coding job to the order.

A round bottle labeling machine can apply a wraparound or partial-wrap label, but accurate placement does not establish product identity. Bottle/SKU checks, a label reader, or a downstream OCR/OCV system may be appropriate depending on the product and installed equipment. Check how curves, seams, and reflections affect readability.

Cartons: several correct components must make one correct pack

A pharmaceutical cartoning machine may insert blisters or bottles, add a leaflet, and close the carton. Correct components can still belong to different orders. The cartoner therefore benefits from clearly identified product and carton materials, reliable leaflet checks, lot/expiry verification, and confirmed rejection of mismatched packs.

These are engineering controls, not universally mandated machine features.

How Does GMP Prevent Pharmaceutical Labeling Errors?

GMP the approved artwork into a controlled production process. In the US, 21 CFR 211.122 and 211.125 address packaging and labeling materials and their issuance; 211.130 and 211.134 address packaging-line controls and finished-pack checks. EU GMP Part I, Chapter 5 similarly covers printed materials, line clearance, overprinting, and in-process inspection.

Why a changeover is a critical labeling control

Return to the 10 mg/20 mg example. The 20 mg job finishes and the team prepares the machine for 10 mg production. One carton remains in the magazine; the printer still stores the previous lot; a spare foil roll sits beside the line. Any one can produce an incorrectly labeled pack.

A proper line clearance removes previous products, labels, cartons, foil, inserts, code samples, and unsuitable records from the work area. The team then issues and checks the approved 10 mg components, resets the printer job, verifies the new line recipe, and documents the clearance. This prevents mix-ups before they reach final inspection.

What the team checks before, during, and after the run

Follow one packaging order from preparation to release:

1. Approve and issue materials. Compare carton, label, foil, and leaflet artwork with the master or batch packaging instructions. Confirm strength, pack size, language, revision, and quantities.
2. Clear and set up the line. Remove the previous job's components. Load the correct product recipe and authorized lot, expiry, and other variable data.
3. Check the first acceptable packs. Examine physical contents, carton/foil/label identity, readable print, and encoded data where applicable. Record the result.
4. Monitor production. Check overprinting and packaging completeness. Where readers, cameras, or reject devices are installed, verify their function under the approved procedure and at defined times.
5. Control rejects and investigate differences. Keep failed packs out of accepted output and control any reintroduction. Investigate unexplained material or quantity discrepancies.
6. Close the batch. Reconcile labeling as applicable, handle unused lot-coded materials correctly, inspect representative finished packs, and complete the packaging record for quality review.

Label reconciliation compares labels issued, used, and returned or otherwise accounted for to reveal unexplained losses or mix-ups. 21 CFR 211.125 provides a specific reconciliation waiver for certain cut or roll labeling when its required 100% examination conditions are met; it does not remove the other label-control duties.

A vision system is useful when the defect can be reliably detected—for example, a missing label, mismatched product code, or failed Data Matrix. It cannot approve artwork, clear old materials, or replace quality review. GMP does not require one universal camera arrangement.

Which Packaging Machines and Printing Methods Help Apply These Controls?

Equipment selection starts with the packaging risks. A pharmaceutical labeling machine places a label on the container; a coding system adds variable information; an inspection system checks defined characteristics; and a cartoning machine brings the final components together. The broad term “pharma labeling machine” hides those differences.

Choose the coder for the package material and information

A batch coding machine or pharmaceutical label printing machine may mark preprinted labels, paperboard cartons, films, or foil. Choose among:

• Thermal inkjet (TIJ) produces compact, high-resolution text and codes on compatible surfaces. Test ink adhesion and contrast on the actual carton or label coating.
• Continuous inkjet (CIJ) applies noncontact marks to moving packs and a broad range of materials. Check ink suitability, drying, and the maintenance required for the planned production pattern.
• Thermal transfer overprinting (TTO) transfers variable print onto compatible flexible films or web materials. Its suitability depends on the ribbon, substrate, and printing arrangement.
• Laser marking creates a mark by interacting with the substrate rather than depositing ink. Confirm that the material responds safely and gives readable contrast without damaging the package.

TIJ may suit a carton while TTO suits compatible film. No method is inherently “more GMP compliant”; test the actual substrate, speed, and print quality.

Connect inspection to an actual reject decision

A vision inspection system can check label presence, artwork identity, OCR/OCV of batch text, or barcode/Data Matrix content. A basic barcode reader tells you whether it can decode a symbol; a barcode verification system can assess the relevant printed-code quality against a specified standard. Both depend on correct inspection recipes.

An alarm without confirmed rejection can leave a bad carton in accepted output. In an integrated blister cartoning line or pharmaceutical bottle packaging line, define the inspection location, reject tracking, failed-pack segregation, and records before approving the configuration.

A clear user requirement specification (URS) should state products, markets, required checks, changeovers, and quality records. Rich Packing can review possible labeling, coding, blister packaging, and automatic cartoning machine configurations against those requirements. The pharmaceutical manufacturer remains responsible for approved labeling and compliance.

Follow each pack from approved artwork to acceptance or rejection. Maintain the link between its identity, printed data, and components so errors are caught before release.

Frequently Asked Questions

References

1. US eCFR — 21 CFR Part 201: Drug Labeling and 21 CFR Part 211: GMP.

2. EUR-Lex — Directive 2001/83/EC.

3. EUR-Lex — Commission Delegated Regulation (EU) 2016/161.

4. EMA — Human Product Information (QRD) Templates.

5. European Commission — EudraLex Volume 4 GMP Guidelines.